Molecular mimicry

’Negative Evidence’ for Neurological Complications of COVID Vaccines Explored in Journal of American Physicians and Surgeons (AAPS)

Retrieved on: 
Tuesday, September 5, 2023
Vaccine, Molecular mimicry, Vaccination, Cranial nerves, Physician, AAPS, Spinal cord, COVID-19, Brain, Research, COVID, Sympathetic nervous system, Messenger, Paralysis, Association of American Physicians and Surgeons, COVID-19 vaccine, Journal, Allergy, Nervous system, Diagnosis, Neurotoxicity, Injury, Pharmaceutical industry, Surgeon

TUCSON, Ariz., Sept. 05, 2023 (GLOBE NEWSWIRE) -- The occurrence of neurological adverse events following COVID vaccines is generally acknowledged, but their significance is downplayed, writes Jane Orient , M.D., in the fall issue of the Journal of American Physicians and Surgeons.

Key Points: 
  • TUCSON, Ariz., Sept. 05, 2023 (GLOBE NEWSWIRE) -- The occurrence of neurological adverse events following COVID vaccines is generally acknowledged, but their significance is downplayed, writes Jane Orient , M.D., in the fall issue of the Journal of American Physicians and Surgeons.
  • The devastating complications such as paralysis that are accepted as known side effects of vaccines are said to be exceedingly rare.
  • Between 2020 and 2023, 73 review papers were published describing sizable case-series of neurological complications of COVID-19 vaccines, but only three articles containing original research examining potential mechanisms.
  • “The highly publicized and coercive ‘lifesaving measures’ now look like a ticking time bomb.”
    The Journal of American Physicians and Surgeons is published by the Association of American Physicians and Surgeons (AAPS) , a national organization representing physicians in all specialties since 1943.

Enterome announces first patient dosed in Phase 2 trial with OncoMimics™ immunotherapy EO2040 in Colorectal Cancer with ctDNA-defined Minimal Residual Disease

Retrieved on: 
Tuesday, July 11, 2023
Molecular mimicry, DNA, Circulating tumor DNA, BIRC5, CRC, Liquid biopsy, Cancer, Immunotherapy, Rated R, Trial of the century, MD Anderson Cancer Center, MRD, Service provider, CD8, FOXM1, Patient, Risk, Colorectal cancer, University, Blood, Somatic mutation, Epitope, Neoplasm, UCP2, DFS, Nivolumab, Pharmaceutical industry, Vaccine, Medical imaging

EO2040 is an innovative, off-the-shelf immunotherapy that combines two synthetic OncoMimics™ peptides.

Key Points: 
  • EO2040 is an innovative, off-the-shelf immunotherapy that combines two synthetic OncoMimics™ peptides.
  • These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with the tumor-associated antigens (TAAs) FOXM1 & BIRC5.
  • EO2040 also includes universal cancer peptide 2 (UCP2), a helper peptide representing the CD4+ epitope.
  • The CLAUDE study (EOCRC1-22; NCT05350501) is the first trial to use liquid biopsy monitoring to measure ctDNA clearance as an indicator of OncoMimics™ immunotherapy efficacy.

Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer

Retrieved on: 
Friday, June 30, 2023
Molecular mimicry, CDC20, CRC, Microsatellite instability, Non-Hodgkin lymphoma, Immune tolerance, Adrenal tumor, Research, Immunotherapy, Glioblastoma, Assistant, Oncology, Colorectal cancer, Service provider, AP-HP, CD8, FOXM1, Patient, Cancer, Epitope, Neoplasm, Sorbonne University, Nivolumab, Safety, UCP2, Peptide, Inflammation, Vaccine, Pharmaceutical industry, Medical imaging, UBE2C

These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with the tumor-associated antigens (TAAs) BIRC5/survivin, FOXM1, UBE2C, CDC20 and KIF2C.

Key Points: 
  • These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with the tumor-associated antigens (TAAs) BIRC5/survivin, FOXM1, UBE2C, CDC20 and KIF2C.
  • EO4010 also includes universal cancer peptide 2 (UCP2), a helper peptide representing the CD4+ epitope.
  • The Company is also initiating a Phase 2 clinical study in patients with ctDNA-defined, Minimal Residual Disease of colorectal cancer, with its fourth candidate EO2040.
  • This groundbreaking approach so far demonstrates both efficacy and safety for the patients, instilling real hope in the fight against cancer.”

Enterome's new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma

Retrieved on: 
Wednesday, June 14, 2023
Molecular mimicry, Rituximab, CD20, ICML, Lenalidomide, Lymphoma, CD268, CD22, Adrenal tumor, Immunotherapy, Glioblastoma, Trial of the century, Protein, CD8, Asilomar International Conference on Climate Intervention Technologies, Patient, Standard of care, Colorectal cancer, Epitope, Neoplasm, Poster, Lymphocyte, CD37, Safety, BAFF, UCP2, Conference, Peptide, Inflammation, Vaccine, Pharmaceutical industry

EO2463 is an innovative, off-the-shelf immunotherapy candidate that combines four synthetic OncoMimic™ peptides.

Key Points: 
  • EO2463 is an innovative, off-the-shelf immunotherapy candidate that combines four synthetic OncoMimic™ peptides.
  • These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with the B lymphocyte-specific lineage markers CD20, CD22, CD37 and CD268 (BAFF receptor).
  • The unique ability of EO2463 immunotherapy to selectively target multiple B cell markers enables the destruction of malignant B lymphocytes that are abundant in iNHL.
  • We are also preparing to enter another new OncoMimics™ candidate, EO4010, for the treatment of metastatic colorectal cancer, into clinical development.”

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award

Retrieved on: 
Thursday, February 16, 2023
Brain mapping, National academy, Physician, Central nervous system, Therapy, National Academy of Sciences, PET, SBMT, Research, PALO, CNS, Molecular mimicry, DSM-IV codes, Association of Environmental Engineering and Science Professors, Nobel Prize, Cure, Immunization, HEPACAM, KTTA, Pharmaceutical industry, Medical imaging, Medicine

This prestigious award is given by the SBMT and the World Brain Mapping Foundation to physicians, engineers, and scientists who have contributed significantly to the field of brain mapping and therapeutics.

Key Points: 
  • This prestigious award is given by the SBMT and the World Brain Mapping Foundation to physicians, engineers, and scientists who have contributed significantly to the field of brain mapping and therapeutics.
  • Past recipients include Nobel Prize winner Dr. Eric Kandel, and Dr. Michael E. Phelps, the pioneer of PET imaging.
  • “MS is a debilitating disease that requires research into effective therapies and innovation in immunization.
  • I dedicate my career to advancing these therapies for the thousands suffering from neurological diseases globally.”

Enterome's OncoMimics™ peptide-based immunotherapy EO2401 generates and maintains elevated anti-tumor T cell responses for more than 10 months in patients with recurrent glioblastoma

Retrieved on: 
Thursday, November 10, 2022
UCP2, Assay, IL13RA2, PFS, Protein, Nivolumab, Bevacizumab, CD4, TAAS, FOXM1, Annual general meeting, Peptide, Immunotherapy, Neoplasm, LDB, Population, Data, Glioblastoma, Safety, Cancer, Vaccination, Observation, Maintenance, Poster, Society for Immunotherapy of Cancer, Molecular mimicry, Patient, Memory, Therapy, BIRC5, ORR, SITC, Vaccine, Pharmaceutical industry

PARIS, Nov. 10, 2022 /PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces updated safety, immunogenicity and efficacy data of its Phase 1/2 clinical trial of EO2401 in combination with an immune checkpoint inhibitor (nivolumab) +/- an anti-VEGF therapy (bevacizumab), for the treatment of patients with first progression/recurrence of glioblastoma (ROSALIE trial). The data were presented in an oral and a poster presentation at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston, MA, US, today.

Key Points: 
  • EO2401 includes synthetically produced HLA-A2 peptides with molecular mimicry to TAAs upregulated in glioblastoma (IL13Ra2, BIRC5 and FOXM1) and the CD4 helper peptide UCP2.
  • EO2401 in combination with nivolumab generated strong systemic immune responses through activation of specific effector memory CD8+ T cells, correlating with clinical efficacy.
  • Additional patients are to be treated with triple combination of EO2401 in combination with nivolumab and bevacizumab to support final regimen selection.
  • The trial is assessing safety, tolerability, immunogenicity and preliminary efficacy in approximately 80 patients at centers in the US and Europe.

Enterome's OncoMimics™ peptide-based immunotherapy EO2401 generates and maintains elevated anti-tumor T cell responses for more than 10 months in patients with recurrent glioblastoma

Retrieved on: 
Thursday, November 10, 2022
UCP2, Assay, IL13RA2, PFS, Protein, Nivolumab, Bevacizumab, CD4, TAAS, FOXM1, Annual general meeting, Peptide, Immunotherapy, Neoplasm, LDB, Population, Data, Glioblastoma, Safety, Cancer, Vaccination, Observation, Maintenance, Poster, Society for Immunotherapy of Cancer, Molecular mimicry, Patient, Memory, Therapy, BIRC5, ORR, SITC, Vaccine, Pharmaceutical industry

PARIS, Nov. 10, 2022 /PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces updated safety, immunogenicity and efficacy data of its Phase 1/2 clinical trial of EO2401 in combination with an immune checkpoint inhibitor (nivolumab) +/- an anti-VEGF therapy (bevacizumab), for the treatment of patients with first progression/recurrence of glioblastoma (ROSALIE trial). The data were presented in an oral and a poster presentation at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston, MA, US, today.

Key Points: 
  • EO2401 includes synthetically produced HLA-A2 peptides with molecular mimicry to TAAs upregulated in glioblastoma (IL13Ra2, BIRC5 and FOXM1) and the CD4 helper peptide UCP2.
  • EO2401 in combination with nivolumab generated strong systemic immune responses through activation of specific effector memory CD8+ T cells, correlating with clinical efficacy.
  • Additional patients are to be treated with triple combination of EO2401 in combination with nivolumab and bevacizumab to support final regimen selection.
  • The trial is assessing safety, tolerability, immunogenicity and preliminary efficacy in approximately 80 patients at centers in the US and Europe.

Enterome to present three abstracts on its novel OncoMimics™ cancer immunotherapies at ASCO 2022

Retrieved on: 
Friday, May 27, 2022
Cancer, Degenerative disease, Patient, Adrenal tumor, Vaccine, Cytokine, IBD, Peptide, Antigen, Molecular mimicry, Glioblastoma, Colorectal cancer, Hormone, Immune system, Protein, Drug discovery, Pharmaceutical industry

PARIS, May 27, 2022 /PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announced the publication of three abstracts related to its OncoMimcs™ pipeline, including EO2401, its first-in-class off-the-shelf OncoMimics™  cancer immunotherapy, ahead of poster presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2022 in Chicago and virtually. 

Key Points: 
  • Enterome's pioneering work on its OncoMimics pipeline leverages the fundamental understanding that the gut is the largest lymphoid organ in the body and is home to most of its memory T-cells.
  • Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases.
  • Enterome is presently advancing two pipelines of drug candidates, OncoMimics and EndoMimics, which have the potential to address cancer, inflammatory and autoimmune diseases, respectively:
    OncoMimics peptides, a pipeline of therapeutic cancer vaccines.
  • A second OncoMimics candidate, EO2463 is in a Phase 1/2 clinical trial for indolent non-Hodgkin lymphomas.

Enterome to present three abstracts on its novel OncoMimics™ cancer immunotherapies at ASCO 2022

Retrieved on: 
Friday, May 27, 2022
Cancer, Degenerative disease, Patient, Adrenal tumor, Vaccine, Cytokine, IBD, Peptide, Antigen, Molecular mimicry, Glioblastoma, Colorectal cancer, Hormone, Immune system, Protein, Drug discovery, Pharmaceutical industry

PARIS, May 27, 2022 /PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announced the publication of three abstracts related to its OncoMimcs™ pipeline, including EO2401, its first-in-class off-the-shelf OncoMimics™  cancer immunotherapy, ahead of poster presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2022 in Chicago and virtually. 

Key Points: 
  • Enterome's pioneering work on its OncoMimics pipeline leverages the fundamental understanding that the gut is the largest lymphoid organ in the body and is home to most of its memory T-cells.
  • Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases.
  • Enterome is presently advancing two pipelines of drug candidates, OncoMimics and EndoMimics, which have the potential to address cancer, inflammatory and autoimmune diseases, respectively:
    OncoMimics peptides, a pipeline of therapeutic cancer vaccines.
  • A second OncoMimics candidate, EO2463 is in a Phase 1/2 clinical trial for indolent non-Hodgkin lymphomas.

Enterome to present world first clinical data with EO2401, its first-in-class off-the-shelf OncoMimics™ therapeutic cancer vaccine, at ASCO 2022

Retrieved on: 
Thursday, May 19, 2022
CD8, Immunotherapy, Company, CD22, Cancer, Annual general meeting, CD37, Oncology, BIRC5, Mimicry, Rituximab, Degenerative disease, 2021 Essex County Council election, Patient, Lenalidomide, CD4, Assay, CD20, Cytokine, Society, American Society of Clinical Oncology, IL13RA2, CD268, Peptide, Antigen, Molecular mimicry, Glioblastoma, ASCO, Colorectal cancer, Therapy, Hormone, FOXM1, Nivolumab, Immune system, Protein, ESMO, CEO, Vaccine, Pharmaceutical industry

PARIS, May 19, 2022 /PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces that it will present for the first time proof-of-concept data from clinical trials with EO2401, its first-in-class off-the-shelf OncoMimics™ cancer immunotherapy at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2022 in Chicago and virtually. 

Key Points: 
  • To-date, Enterome has generated a repertoire of OncoMimics peptides correlating to tumor antigens across a wide range of solid and liquid tumor types.
  • From this, the Company is creating a pipeline of off-the-shelf cancer immunotherapies designed to act via the same novel mode of action.
  • EO2463 combines four OncoMimics peptides that exhibit molecular mimicry with the B cell markers CD20, CD22, CD37, and CD268 (BAFF-receptor), respectively.
  • "We are thrilled to be able to present the first clinical data demonstrating the potential of our unique OncoMimics pipeline at ASCO this year.